<DOC>
	<DOCNO>NCT02075996</DOCNO>
	<brief_summary>The purpose non-interventional study collect data efficiency safety pomalidomide combination dexamethasone routine application</brief_summary>
	<brief_title>Non-interventional Study With Pomalidomide ( Imnovid® )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients relapse refractory multiple myeloma Patients must receive least two prior line treatment ( induction therapy follow stem cell transplantation ± maintenance therapy consider one prior therapy ) must progress recent therapy regimen Adult male female patient ( least 18 year upper age limit ) Written informed consent data collection pseudonymized data transfer The condition Pregnancy Prevention Programme must fulfil patient unless reliable evidence patient childbearing potential ( see summary product characteristic Imnovid® ) Other criterion accord summary product characteristic Imnovid® Missing patient 's informed consent Pregnant breastfeed woman Male patient , capable complying require preventive measure ( see summary product characteristic Imnovid® ) Other criterion accord summary product characteristic Imnovid®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pomalidomide , Imnovid , dexamethasone , Poseidon , multiple myeloma , daily routine , secondary malignancy , Germany , non-interventional study , safety ,</keyword>
</DOC>